Can-Fite BioPharma announced it published an article in the Experimental and Therapeutic Medicine Journal, titled “Long-term complete response to namodenoson in liver cancer with Child-Pugh B cirrhosis: A case report”. The patient participated in the Phase II Liver Cancer Study and has been treated with namodenoson for greater than 7 years under compassionate use program. The article describes a patient with advanced liver cancer that was enrolled in the former Can-Fite Phase II study, continues to receive treatment with namodenoson, and has now an overall survival of greater than 7 years, with disappearance of ascites, normal liver function, good quality of life and defined as a long-term complete response.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite’s Namodenoson Shows Promise for Liver Cancer
- Can-Fite: Article by KOL presents Namodenoson to treat liver cancer, MASH
- Can-Fite Advances MASH Treatment into Phase IIb
- Can-Fite BioPharma submits IND to FDA for Phase IIb trial of namodenoson
- US Investors Beware: Tax Complications for Can-Fite BioPharma Shareholders
